Literature DB >> 30076907

Long-Term Surveillance of Complex Cystic Renal Masses and Heterogeneity of Bosniak 3 Lesions.

Deepak K Pruthi1, Qianqian Liu2, Iain D C Kirkpatrick3, Jonathan Gelfond2, Darrel E Drachenberg4.   

Abstract

PURPOSE: We sought to better characterize the frequency of Bosniak cyst class changes, identify predictors of change and progression, determine the average growth rate of cysts and validate the safety of active surveillance.
MATERIALS AND METHODS: Consecutive patients referred for the management of complex cysts (Bosniak 2F or greater) were included in analysis. All imaging studies were reevaluated and any stage change was reviewed with a blinded genitourinary radiologist. Bosniak 3 cysts were subclassified as 3s-septated enhancing Bosniak cysts and 3n-cysts with wall or septation-only nodularity. A multivariate Cox proportional hazards model was used to identify predictors of the Bosniak classification change. Kaplan-Meier curves were applied to analyze Bosniak cyst progression and regression.
RESULTS: A total 140 lesions were included in study, necessitating review of a total of 1,011 abdominal scans in 111 patients. Median followup was 46 months (IQR 23-65.5) and patients underwent a mean of 6.8 diagnostic scans. On multivariate analysis nodular cysts progressed (HR 6.16, 95% CI 2.58-14.72, p <0.00004) and entirely endophytic cysts were less likely to progress (HR 0.21, 95% CI 0.05-0.85, p = 0.028). On Kaplan-Meier analysis Bosniak 3s cysts were more likely to regress while Bosniak 3n cysts were more likely to progress than 3s cysts (p = 0.0178 and 0.0002, respectively). The growth rate of 3n and 2F cysts was 0.19 and 0.11 cm per year (p = 0.0493 and 0.0327, respectively). Locally advanced or metastatic disease did not develop in any patient.
CONCLUSIONS: A diagnostic change in Bosniak 3s and 2F cysts is common and Bosniak 3n cysts behave more like Bosniak 4 cysts. Most complex kidney cysts can be safely monitored without intervention and the interval between serial imaging procedures should be increased.
Copyright © 2018 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  classification; cysts; decision making; diagnostic imaging; kidney neoplasms

Mesh:

Year:  2018        PMID: 30076907     DOI: 10.1016/j.juro.2018.07.063

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

1.  Malignancy risk stratification of cystic renal lesions based on a contrast-enhanced CT-based machine learning model and a clinical decision algorithm.

Authors:  Jérémy Dana; Thierry L Lefebvre; Peter Savadjiev; Sylvain Bodard; Simon Gauvin; Sahir Rai Bhatnagar; Reza Forghani; Olivier Hélénon; Caroline Reinhold
Journal:  Eur Radiol       Date:  2022-01-23       Impact factor: 5.315

2.  Management of complex renal cysts in Canada: results of a survey study.

Authors:  Félix Couture; Antonio Finelli; Amélie Tétu; Bimal Bhindi; Rodney H Breau; Anil Kapoor; Wassim Kassouf; Luke Lavallée; Simon Tanguay; Philippe D Violette; Patrick O Richard
Journal:  BMC Urol       Date:  2020-04-28       Impact factor: 2.264

Review 3.  Imaging Characterization of Renal Masses.

Authors:  Carlos Nicolau; Natalie Antunes; Blanca Paño; Carmen Sebastia
Journal:  Medicina (Kaunas)       Date:  2021-01-08       Impact factor: 2.430

4.  Role of contrast-enhanced ultrasound in assessing indeterminate renal lesions and Bosniak ≥2F complex renal cysts found incidentally on CT or MRI.

Authors:  Giuseppe Como; Claudio Valotto; Francesco Tulipano Di Franco; Gianluca Giannarini; Lorenzo Cereser; Rossano Girometti; Chiara Zuiani
Journal:  Br J Radiol       Date:  2021-08-31       Impact factor: 3.039

5.  Active surveillance versus initial surgery in the long-term management of Bosniak IIF-IV cystic renal masses.

Authors:  Lassi Luomala; Juhana Rautiola; Petrus Järvinen; Tuomas Mirtti; Harry Nisén
Journal:  Sci Rep       Date:  2022-06-17       Impact factor: 4.996

6.  Complex renal cysts (Bosniak ≥IIF): interobserver agreement, progression and malignancy rates.

Authors:  James Lucocq; Sanjay Pillai; Richard Oparka; Ghulam Nabi
Journal:  Eur Radiol       Date:  2020-08-27       Impact factor: 5.315

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.